Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alvotech SA ALVO

Healthcare Biotechnology
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating... see more

Recent & Breaking News (NDAQ:ALVO)

Alvotech Reports Financial Results for the First Nine Months of 2024

GlobeNewswire November 13, 2024

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

GlobeNewswire November 7, 2024

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

GlobeNewswire November 4, 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

GlobeNewswire October 30, 2024

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024

GlobeNewswire October 25, 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

GlobeNewswire October 10, 2024

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

GlobeNewswire September 25, 2024

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 26, 2024

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

GlobeNewswire August 15, 2024

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

GlobeNewswire August 15, 2024

Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

GlobeNewswire August 1, 2024

STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

GlobeNewswire July 22, 2024

Alvotech Announces Closing of Private Debt Financing

GlobeNewswire July 11, 2024

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

GlobeNewswire July 2, 2024

Alvotech Issues New Shares to Holders of Convertible Bonds

GlobeNewswire July 1, 2024

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

GlobeNewswire July 1, 2024

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

GlobeNewswire June 26, 2024

Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

GlobeNewswire June 18, 2024

Alvotech and STADA add to strategic alliance through denosumab partnership

GlobeNewswire June 11, 2024

Alvotech Announces Strategic Refinancing Agreement

GlobeNewswire June 7, 2024